Cambridge Sleep Sciences partnership announcement

RNS Number : 8710R
Barkby Group PLC (The)
11 March 2021
 

11 March 2021

 

The Barkby Group PLC

 

("Barkby" or the "Company")

 

New partnership explores the impact of sleep technology on Parkinson's

 

The Barkby Group is pleased to announce that its subsidiary, Cambridge Sleep Sciences, has signed a collaboration agreement with Parkinson's Concierge to help address sleep issues associated with Parkinson's Disease.

 

Sleep disturbance is common for those living with Parkinson's and can include such symptoms as drowsiness, fatigue, anxiety and other mental health problems. According to the Michael J. Fox Foundation, "many people with Parkinson's have trouble falling or staying asleep at night. Sleep problems can arise from Parkinson's motor or non-motor symptoms, medication side effects or other conditions that affect sleep."1

 

Cambridge Sleep Sciences has developed SleepHub®, a device that has been shown to improve sleep in people with insomnia, and will be working with Parkinson's Concierge to assess the efficacy of SleepHub® in people with Parkinson's prior to undertaking formal clinical trials.

 

Dr Chris Dickson, Executive Chairman of Cambridge Sleep Sciences, said: "People living with Parkinson's commonly experience disrupted sleep, and when Parkinson's Concierge advised us of anecdotal reports that SleepHub® had improved sleep in some of their members, we wanted to explore this further. Parkinson's Concierge, with their global community of members, made the natural partnership with which to investigate the potential benefits."

 

SleepHub® is the result of more than a decade of research and development. Users are helped to achieve quality sleep through scientifically formulated sounds, delivered using a pair of premium speakers, that use specific beats and pulses to modulate sleep patterns.

 

Parkinson's Concierge provide support to people affected by Parkinson's. There are 147,000 people in the UK with Parkinson's and 10 million worldwide.

 

Charlotte Allen and Russ Bradford, Co-Founders of Parkinson's Concierge, said: "We are very excited by our partnership with Cambridge Sleep Sciences and have high hopes for SleepHub® improving the lives of many people living with Parkinson's. At Parkinson's Concierge we always seek out products and services, gadgets, tech and AI solutions which can benefit people living with this condition. We are extremely optimistic, having tested SleepHub® for about a month now, that this could have an effect on improving the other symptoms people live with as well for our Global Parkinson's Community."

 

ENDS

 

 

1 Michael J. Fox Foundation: Fatigue & sleep  

 

Enquiries: 

 

The Barkby Group PLC


Charles Dickson, Executive Chairman

Douglas Benzie, Chief Financial Officer

 




finnCap Ltd (Nomad and Broker)

+44 (0) 20 7220 0500

Carl Holmes/Simon Hicks (corporate finance)

Tim Redfern/Richard Chambers (ECM)

 


Camarco (Financial PR)

+44 (0) 20 3757 4994

Jennifer Renwick/Jake Thomas

 


 

About The Barkby Group Plc:

The Barkby Group PLC is a diversified group of high growth, high quality businesses run by an entrepreneurial and experienced management team. The existing wholly owned businesses within Barkby include; Commercial Property Development, Barkby Hospitality (comprising Barkby Pubs and Workshop Coffee) and Centurian Automotive.

 

In addition to these businesses, Barkby Life Sciences has invested in Verso Biosense (formerly known as Vivoplex), a digital health company aiming to transform Women's Health with precision medicine, and it has signed an agreement with Cambridge Sound Technologies UK Ltd for the exclusive design of, and acquisition of the intellectual property rights related to, a device to improve and facilitate natural sleep.

 

Barkby's strategy is to accelerate and maximise opportunities within its existing businesses as well as continue to source and invest in cash generative, growth businesses with the ability to disrupt.

About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, part of the Life Sciences division of The Barkby Group Plc, develop technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, they develop innovative products that improve quality of life and re-energise lives.

 

The company prides itself on delivering the first neuroscience-based sleep product, SleepHub®, to help improve and facilitate natural sleep.

 

Find out more at: www.cambridgesleepsciences.com

 

About Parkinson's Concierge

Parkinson's Concierge are Parkinson's experts and advisory consultants, connectors and awareness creators of living with Parkinson's.

 

The organisation develops relationships & long term partnerships with organisations who can make change happen - supporting them to develop and deliver products and services which improve the quality of life for people living with Parkinson's.

 

Parkinson's Concierge have created a global affiliate healthcare platform which connects charities, partners and leading global medical professionals to each other and the Parkinson's community.

 

Find out more at: https://parkinsonsconcierge.com  

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBLLFFXLFBBB
UK 100